DOCSLIB.ORG

<Peptide Catalogue>

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
<Peptide Catalogue> <Peptide catalogue> Catalog # Peptide Name 2001 Amylin (cat) (IAPP (cat)) 2002 Amylin (rat) 2003 Amylin (8-37) (rat) 2004 Acetyl-Amylin (8-37) (rat) 2005 Amylin (20-29) (human) 2006 Amylin Antagonist AC187 2007 Amylin Antagonist AC253 2008 Amyloid b-protein (1-42) 2009 Amyloid b-protein (1-40) 2010 Amyloid b-Protein (1-28) (SP28) 2011 [Gln11]-Amyloid b-Protein (1-28) 2012 Amyloid b-protein (1-16) 2013 Amyloid b-protein (10-20) 2014 Amyloid b-Protein (12-28) (SP17) 2015 Amyloid b-Protein (22-35) 2016 Amyloid b-Protein (25-35) 2017 Amyloid b/A4 Protein Precursor (96-110) Analog 2018 Amyloid b/A4 Protein Precursor (135-155) 2019 Amyloid b/A4-Protein Precursor (328-332) 2020 Amyloid b/A4 Protein Precursor (657-676) 2021 Non-Ab Component of Alzheimer’s Disease Amyloid (NAC) 2022 Amyloid P Component (33-38) amide 2023 Corticotropin (ACTH (1-39) (human)) 2024 ACTH (1-39) (rat) 2025 ACTH (1-24) (human) (Tetracosactide) 2026 [Phe2, Nle4]-ACTH (1-24) (human) 2027 Acetyl-ACTH (1-17) 2028 ACTH (1-14) 2029 Acetyl-ACTH (1-14) 2030 ACTH (4-11) 2031 ACTH (4-10) 2032 ACTH (4-9) 2033 ACTH (5-10) 2034 ACTH (6-24) (human) 2035 ACTH (11-24) (human) 2036 ACTH (22-39) (human) (beta-Cell-Tropin) 2037 ACTH (34-39) 2038 Angiotensin I (human) 2039 Acetyl-Angiotensin I (human) 2040 [Asn1, Val5]-Angiotensin I (goosefish) 2041 [Asn1, Val5, Asn9]-Angiotensin I(Angiotensin I (salmon)) 2042 [des-Asp1]-Angiotensin I (human) 2043 Angiotensin II (human) 2044 [p-amino-Phe6]-Angiotensin II 2045 [Asn1, Val5]-Angiotensin II 2046 [3,5-Diiodo-Tyr4]-Angiotensin II 2047 [Sar1]-Angiotensin II 2048 [Sar1, Ala8]-Angiotensin II 2049 [Sar1, Gly8]-Angiotensin II 2050 [Sar1, Ile8]-Angiotensin II 2051 [Sar1, Leu8]-Angiotensin II 2052 [Sar1, Thr8]-Angiotensin II 2053 [Sar1, Val5, Ala8]-Angiotensin II(Saralasin) 2054 [Ile3, Val5]-Ala-Pro-Gly Angiotensin II 2055 [Sar1]-Angiotensin II (1-7) amide 2056 Angiotensin II (1-4 2057 Angiotensin II (3-8) 2058 Angiotensin II (4-8) 2059 Angiotensin II (5-8) 2060 Angiotensin I/II (1-7) 2061 [D-Ala7]-Angiotensin I/II (1-7) 2062 Angiotensin I/II (1-6) 2063 Angiotensin I/II (1-5) 2064 Angiotensin II Antagonist 2065 Angiotensin II Antipeptide 2066 Angiotensin III ([des-Asp1]-Angiotensin II) 2067 [Ile7]-Angiotensin III(Angiotensin III lnhibitor) 2068 [Val4]-Angiotensin III 2069 Angiotensin III Antipeptide 2070 Angiogenin (108-123) 2071 Astressin-B 2072 Atrial Natriuretic Factor (1-29) (chicken 2073 Atrial Natriuretic Factor (eel) 2074 Atrial Natriuretic Factor (1-30) (frog) 2075 Atrial Natriuretic Factor (1-28 ) (human, canine) 2076 Atrial Natriuretic Factor (1-28) (rat) 2077 [Met (O)12]-ANF (1-28) (human, canine) 2078 ANF (1-24) (frog) 2079 ANF (3-28) (human, canine) 2080 ANF (4-28) (human, canine) 2081 ANF (7-28) (human, canine) 2082 ANF (11-30) (frog) 2083 Atriopeptin I (rat, rabbit, mouse) 2084 Atriopeptin II (rat, rabbit, mouse) 2085 Atriopeptin III (rat, rabbit, mouse) 2086 mini-ANP ([Met5, Cys6,17, His7, Ser16, Tyr18, Arg19]-rANF (5-19) amide) 2087 Adrenomedullin (1-52) (human 2088 Adrenomedullin (1-50) (rat 2089 Adrenomedullin (13-52) (human 2090 Adrenomedullin (22-52) (human) 2091 proAM-N20 (human) (Proadrenomedullin N-Terminal 20 Peptide (human)) 2092 proAM-N20 (rat) (Proadrenomedullin N-Terminal 20 Peptide (rat) 2093 Allatostatin I 2094 Allatostatin II 2095 Allatostatin IV 2096 Type B Allatostatin 2097 Adipokinetic Hormone G (Gryllus bimaculatus) (AKH-G) 2098 Adipokinetic Hormone (Locust) 2099 Adipokinetic Hormone (Heliothis zea and Manduca sexta) 2100 Adipokinetic Hormone II (Locusta migratoria) (AKH II-L) 2101 Adipokinetic Hormone II (Schistocera gregaria) (AKH II-S) 2102 [Tyr1]-Adipokinetic Hormone (locust) 2103 (ACE inhibitor) 2104 GAPDH Peptide (79-86) (porcine) 2105 Antho-RFamide 2106 Antho-RPamide I 2107 Antho-RPamide II 2108 Antho-RWamide I 2109 Antho-RWamide II 2110 Bombinin-like Peptide (BLP-1) 2111 Dermaseptin 2112 Indolicidin 2113 Lytic Peptide SB-37 2114 Lytic Peptide Shiva-1 2115 Anti-Inflammatory Peptide 1 2116 Anti-lnflammatory Peptide 2 2117 Anti-lnflammatory Peptide 3 2118 Metorphamide (Adrenorphin, Proenkephalin (206-213) (bovine)) 2119 Metorphamide (free Acid) (Adrenorphin (free acid)) 2120 Aldosterone Secretion Inhibitory Factor (1-35) (bovine) (ASIF) 2121 Anantin (linear sequence) 2122 Anorexigenic Peptide 2123 Antiarrhythmic Peptide (AAP) 2124 Antiestrogen 2125 Anti-Kentsin 2126 Antistasin-Related Peptide (D-Arg32)-Antistasin (32-38) 2127 Apamin (honey bee, Apis melifera) 2128 Autocamtide-2 2129 Autocamtide-2-Related Inhibitory Peptide 2130 Biotinyl-ACTH (1-24) (human) 2131 Biotinyl-ACTH (7-38) (human) (Biotinyl-Corticotropin Inhibiting Peptide, Biotinyl-CIP 2132 Biotinyl-ACTH (18-39) (human) 2133 Biotinyl-Angiotensin I (human) 2134 Biotinyl-Angiotensin II (human) 2135 Biotinyl-Ala-Ala-Ala-Angiotensin II 2136 Biotinyl-ANF (1-28) (human, canine) 2137 Biotinyl-ANF (1-28) (rat) 2138 Biotinyl-Bombesin 2139 Biotinyl-Bradykinin 2140 Biotinyl-BNP-45 (rat) 2141 Biotinyl-BNP-32 (human) 2142 Biotinyl-BNP-32 (porcine) 2143 Biotinyl-BNP-32 (rat) 2144 Biotinyl-BNP-26 (porcine) 2145 Biotinyl-b-CGRP (human) 2146 Biotinyl-Leu-Enkephalin 2147 Biotinyl-Met-Enkephalin 2148 Biotinyl-Galanin (porcine) 2149 Biotinyl-Galanin (rat) 2150 Biotinyl-Gastrin I (human) 2151 Biotinyl-Gastrin Releasing Peptide (porcine) 2152 Biotinyl-Glucagon (1-37) (porcine) 2153 Biotinyl-Glucagon (1-29) (human, bovine, porcine) 2154 Biotinyl-Glucagon-like Peptide 1 (1-36) amide (human) 2155 Biotinyl-Glucagon-like Peptide 1 (7-36) amide (human) (Biotinyl-Preproglucagon amide (78- 107)) 2156 Biotinyl-Glucagon-like Peptide 2 (human) (Biotinyl-Preproglucagon (126-159)) 2157 Biotinyl-GRF (human) (1-44) 2158 Biotinyl-GRF (1-44) (ovine) 2159 Biotinyl-GRF (1-44) (porcine) 2160 Biotinyl-GRF (1-43) (rat) 2161 Biotinyl-LH-RH (human) 2162 Biotinyl-Magainin 1 2163 Biotinyl-Magainin 2 2164 Biotinyl-MCH (human, mouse, rat) 2165 Biotinyl-Motilin (canine) 2166 Biotinyl-Motilin (human, porcine) 2167 Biotinyl-Neurokinin A 2168 Biotinyl-Neurokinin B 2169 Biotinyl-Neuromedin B (porcine) 2170 Biotinyl-Neuromedin C (porcine) 2171 Biotinyl-Neuropeptide K (1-36) (porcine) 2172 Biotinyl-Neuropeptide Y (human, rat) 2173 Biotinyl-Neuropeptide Y (13-36) (porcine) 2174 Biotinyl-Neurotensin 2175 Biotinyl-Oxytocin 2176 Biotinyl-Pancreastatin (porcine) 2177 Biotinyl-Pancreatic Polypeptide (human) 2178 Biotinyl-Pancreatic Polypeptide (rat) 2179 Biotinyl-Parathyroid Hormone (64-84) (human) 2180 Biotinyl-PYY (human) 2181 Biotinyl-PYY (porcine, rat) 2182 Biotinyl-Preangiotensiongen (1-14) (human) 2183 Biotinyl-Renin Substrate Tetradecapeptide (Biotinyl-Angiotensinogen (1-14) (porcine)) 2184 Biotinyl-[Leu8, D-Trp22, Tyr25]-Somatostatin-28 2185 Biotinyl-Substance P 2186 Biotin-NTE-[Arg3]-Substance P 2187 Biotinyl-Thyrotropin-Releasing Hormone 2188 [D-Phe12]-Bombesin 2189 Bombesin (8-14) 2190 Bradykinin 2191 [Ala2,6, des-Pro3]-Bradykinin 2192 [Hyp3]-Bradykinin 2193 Ile-Ser-Bradykinin (T-Kinin) 2194 Lys-Bradykinin (Kallidin) 2195 [Lys0, Ala3]-Bradykinin 2196 [Lys0, des-Arg9]-Bradykinin ([des-Arg10]-Kallidin) 2197 [Lys0, des-Arg9, Tyr8]-Bradykinin ([Tyr9]-Kallidin) 2198 [Lys0, Hyp3]-Bradykinin 2199 Met-Lys-Bradykinin 2200 [Thr6]-Bradykinin 2201 [Tyr0]-Bradykinin 2202 [Tyr5]-Bradykinin 2203 [Tyr8]-Bradykinin 2204 [des-Arg1]-Bradykinin 2205 [des-Arg9]-Bradykinin 2206 [des-Arg9, Leu8]-Bradykinin 2207 [des-Pro2]-Bradykinin (Angiotensin I Converting Enzyme inhibitor) 2208 Bradykinin (1-7) 2209 Bradykinin (1-6) 2210 Bradykinin (1-5) 2211 Bradykinin (2-7) 2212 (Bradykinin-like neuropeptide from Aplysia Californica) 2213 A-VI-5 2214 BPP 5a 2215 BPP 9a (SQ 20881) 2216 BPP B 2217 BPP C 2218 BNP-45 (mouse) 2219 BNP-45 (rat) (BNP (51-95), 5K Cardiac Natriuretic Peptide) 2220 BNP-26 (porcine) 2221 BAM-12P 2222 BAM-12P (7-12) 2223 BAM-18P 2224 BAM-22P 2225 BAM-3200 (Peptide E) 2226 a Bag Cell Peptide (1-9) 2227 Band 3 Protein (547-553) (human) 2228 Band 3 Protein (824-829) (human) 2229 Bactenecin (bovine) 2230 Bifunctional Antiplatelet Agent 2231 Brain-Binding Peptide 2232 Buccalin 2233 Bursin 2234 Calcitonin (chicken) 2235 Calcitonin (eel) 2236 Calcitonin (porcine) 2237 Calcitonin (rat) 2238 Calcitonin (salmon) 2239 Calcitonin C-terminal Adjacent Peptide (rat) (CAP or CCP) 2240 Calcitonin C-Terminal Flanking Peptide (human) (C-Procalcitonin, Katacalcin, PDN-21) 2241 a-CGRP (8-37) (rat) 2242 b-CGRP (rat) 2243 b-Casomorphin (bovine) 2244 b-Casomorphin (human) 2245 b-Casomorphin (1-6) (bovine) 2246 b-Casomorphin (1-5) (bovine) 2247 b-Casomorphin (1-5) amide (bovine) 2248 b-Casomorphin (1-4) (bovine) 2249 [Val3]-b-Casomorphin (1-4) amide (bovine) 2250 b-Casomorphin (1-3) amide 2251 [D-Ala2]-b-Casomorphin (1-3) amide 2252 Cholecystokinin (1-21) 2253 Cholecystokinin Octapeptide (desulfated) (CCK (26-33) (desulfated)) 2254 Cholecystokinin Octapeptide free acid (desulfated 2255 Cholecystokinin Octapeptide (1-4) (desulfated) 2256 Cholecystokinin Tetrapeptide CCK-4, Cholecystokinin Octapeptide (5-8), Gastrin Tetrapeptide, Gastrin (14-17) (human)) 2257 CCK Flanking Peptide (desulfated) 2258 Prepro-CCK Fragment V-9-M (rat) 2259 CRF (bovine) 2260 CRF (human, rat) 2261 CRF (ovine) 2262 [Tyr0]-CRF (human, rat) 2263 [Tyr0]-CRF (ovine) 2264 CRF (6-33) (human, rat) 2265 a-Helical CRF (9-41) 2266 Prepro-CRF (125-151) (human) 2267 [Trp63, Trp64]-C3a (63-77) 2268 [Fmoc-Glu70, Ala71,72, Lys74]-C3a (70-77) 2269 Dynorphin A (Prodynorphin (207-223) (human), Prodynorphin (209-225) (porcine)) 2270 Dynorphin A amide 2271 Dynorphin A (1-13) 2272 Dynorphin A (1-13) amide 2273 [D-Ala2]-Dynorphin A (1-13) amide 2274 [D-Arg6]-Dynorphin
Load more

Recommended publications
  • Amylase Release from Rat Parotid Gland Slices C.L
    Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses.
    [Show full text]
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Cellular Responses to Erbb-2 Overexpression in Human Mammary Luminal Epithelial Cells: Comparison of Mrna and Protein Expression
    British Journal of Cancer (2004) 90, 173 – 181 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression SL White1, S Gharbi1, MF Bertani1, H-L Chan1, MD Waterfield1 and JF Timms*,1 1 Ludwig Institute for Cancer Research, Wing 1.1, Cruciform Building, Gower Street, London WCIE 6BT, UK Microarray analysis offers a powerful tool for studying the mechanisms of cellular transformation, although the correlation between mRNA and protein expression is largely unknown. In this study, a microarray analysis was performed to compare transcription in response to overexpression of the ErbB-2 receptor tyrosine kinase in a model mammary luminal epithelial cell system, and in response to the ErbB-specific growth factor heregulin b1. We sought to validate mRNA changes by monitoring changes at the protein level using a parallel proteomics strategy, and report a surprisingly high correlation between transcription and translation for the subset of genes studied. We further characterised the identified targets and relate differential expression to changes in the biological properties of ErbB-2-overexpressing cells. We found differential regulation of several key cell cycle modulators, including cyclin D2, and downregulation of a large number of interferon-inducible genes, consistent with increased proliferation of the ErbB-2- overexpressing cells. Furthermore, differential expression of genes involved in extracellular matrix modelling and cellular adhesion was linked to altered adhesion of these cells. Finally, we provide evidence for enhanced autocrine activation of MAPK signalling and the AP-1 transcription complex.
    [Show full text]
  • Identification of a Novel Vasodilatory Octapeptide from the Skin Secretion
    molecules Article Identification of a Novel Vasodilatory Octapeptide from the Skin Secretion of the African Hyperoliid Frog, Kassina senegalensis Qiang Du 1,†, Hui Wang 1,*,†, Chengbang Ma 2, Yue Wu 2, Xinping Xi 2,*, Mei Zhou 2 ID , Tianbao Chen 2 ID , Chris Shaw 2 and Lei Wang 2 1 School of Pharmacy, China Medical University, Shenyang 110001, Liaoning, China; [email protected] 2 Natural Drug Discovery Group, School of Pharmacy, Queen’s University, Belfast BT9 7BL, Northern Ireland, UK; [email protected] (C.M.); [email protected] (Y.W.); [email protected] (M.Z.); [email protected] (T.C.); [email protected] (C.S.); [email protected] (L.W.) * Correspondence: [email protected] (H.W.); [email protected] (X.X.); Tel.: +86-24-2325-6666 (H.W.); +44-28-9097-2200 (X.X.); Fax: +86-2325-5471 (H.W.); +44-28-9094-7794 (X.X.) † These authors contributed equally to this work. Received: 5 July 2017; Accepted: 19 July 2017; Published: 19 July 2017 Abstract: The defensive skin secretions of amphibians continue to be an excellent source of novel biologically-active peptides. Here we report the identification and pharmacological activity of a novel C-terminally amided myotropic octapeptide from the skin secretion of the African hyperoliid frog, Kassina senegalensis. The 8-amino acid peptide has the following primary structure: WMSLGWSL-amide and has a molecular mass of 978 Da. The primary structure and organisation of the biosynthetic precursor of WL-8 amide was successfully deduced from cloned skin secretion-derived cDNA.
    [Show full text]
  • An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional D
    J Mol Cell Cardiol 32, 2187–2193 (2000) doi:10.1006/jmcc.2000.1241, available online at http://www.idealibrary.com on An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor Claire L. Neilan1, Erin Kenyon1, Melissa A. Kovach1, Kristin Bowden1, William C. Claycomb2, John R. Traynor3 and Steven F. Bolling1 1Department of Cardiac Surgery, University of Michigan, B558 MSRB II, Ann Arbor, MI 48109-0686, USA, 2Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, LA 70112, USA and 3Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632, USA (Received 17 March 2000, accepted in revised form 30 August 2000, published electronically 25 September 2000) C. L. N,E.K,M.A.K,K.B,W.C.C,J.R.T S. F. B.An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor. Journal of Molecular and Cellular Cardiology (2000) 32, 2187–2193. The present study characterizes opioid receptors in an immortalized myocyte cell line, HL-1. Displacement of [3H]bremazocine by selective ligands for the mu (), delta (), and kappa () receptors revealed that only the -selective ligands could fully displace specific [3H]bremazocine binding, indicating the presence of only the -receptor in these cells. Saturation binding studies with the -antagonist naltrindole 3 afforded a Bmax of 32 fmols/mg protein and a KD value for [ H]naltrindole of 0.46 n. The binding affinities of various ligands for the receptor in HL-1 cell membranes obtained from competition binding assays were similar to those obtained using membranes from a neuroblastoma×glioma cell line, NG108-15.
    [Show full text]
  • Characterisation and Partial Purification of a Novel Prohormone Processing Enzyme from Ovine Adrenal Medulla
    Volume 246, number 1,2, 44-48 FEB 06940 March 1989 Characterisation and partial purification of a novel prohormone processing enzyme from ovine adrenal medulla N. Tezapsidis and D.C. Parish Biochemistry Group, School of Biological Sciences, University of Sussex, Falmer, Brighton, Sussex, England Received 3 January 1989 An enzymatic activity has been identified which is capable of generating a product chromatographically identical with adrenorphin from the model substrate BAM 12P. This enzyme was purified by gel filtration and ion-exchange chromatog- raphy and characterised as having a molecular mass between 30 and 45 kDa and an acidic pL The enzyme is active at the acid pH expected in the secretory vesicle interior and is inhibited by EDTA, suggesting that it is a metalloprotease. This activity could not be mimicked by incubation with lysosomal fractions and it meets the criteria to be considered as a possible prohormone processing enzyme. Prohormone processing; Adrenorphin; Secretory vesiclepurification 1. INTRODUCTION The purification of an endopeptidase responsi- ble for the generation of adrenorphin was under- Active peptide hormones are released from their taken, using the ovine adrenal medulla as a source. precursors by endoproteolytic cleavage at highly Adrenorphin is known to be located in the adrenal specific sites. The commonest of these is cleavage medulla of all species so far investigated [6]. at pairs of basic residues such as lysine and Secretory vesicles (also known as chromaffin arginine [1,2]. However another common class of granules) were isolated as a preliminary purifica- processing sites are known to be at single arginine tion step, since it is known that prohormone pro- residues, adjacent to a proline [3].
    [Show full text]
  • Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
    Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain.
    [Show full text]
  • Genscript Product Catalog 2013-2014 Genscript Product Catalog
    GenScript Product Catalog 2013-2014 GenScript Product Catalog www.genscript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854USA Tel: 1-732-885-9188 / 1-732-885-9688 Toll-Free Tel: 1-877-436-7274 Fax: 1-732-210-0262 / 1-732-885-5878 Email: [email protected] Nucleic Acid Purification and Analysis Business Development Tel: 1-732-317-5088 PCR PCR and Cloning Email: [email protected] Protein Analysis Antibodies 2013-2014 Peptides Welcome to GenScript GenScript USA Incorporation, founded in 2002, is a fast-growing biotechnology company and contract research organization (CRO) specialized in custom services and consumable products for academic and pharmaceutical research. Built on our assembly-line mode, one-stop solutions, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of products and services at the most competitive prices in the industry to meet your research needs every day. Over the years, GenScript’s scientists have developed many innovative technologies that allow us to maintain our position at the cutting edge of biological and medical research while offering cost-effective solutions for customers to accelerate their research. Our advanced expertise includes proprietary technology for custom gene synthesis, OptimumGeneTM codon optimization technology, CloneEZ® seamless cloning technology, FlexPeptideTM technology for custom peptide synthesis, BacPowerTM technology for protein expression and purification, T-MaxTM adjuvant and advanced nanotechnology for custom antibody production, as well as our ONE-HOUR WesternTM detection system and eStain® protein staining system. GenScript offers a broad range of reagents, optimized kits, and system solutions to help you unravel the mysteries of biology. We also provide a comprehensive portfolio of customized services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Endothelin-2 Signaling in the Neural Retina Promotes the Endothelial Tip Cell State and Inhibits Angiogenesis
    Endothelin-2 signaling in the neural retina promotes PNAS PLUS the endothelial tip cell state and inhibits angiogenesis Amir Rattnera,1, Huimin Yua, John Williamsa,b, Philip M. Smallwooda,b, and Jeremy Nathansa,b,c,d,1 Departments of aMolecular Biology and Genetics, cNeuroscience, and dOphthalmology and bHoward Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205 Contributed by Jeremy Nathans, August 20, 2013 (sent for review February 19, 2013) Endothelin signaling is required for neural crest migration and time lapse imaging studies of vascular development in zebrafish homeostatic regulation of blood pressure. Here, we report that and mammalian EC dynamics in explant culture show that the tip constitutive overexpression of Endothelin-2 (Edn2) in the mouse cell and stalk cell states are highly plastic, with frequent retina perturbs vascular development by inhibiting endothelial cell exchanges between the two cell states (8, 9). migration across the retinal surface and subsequent endothelial Several other signaling pathways are also essential for retinal cell invasion into the retina. Developing endothelial cells exist in vascular development. Norrin, a Muller-glia–derived ligand, and one of two states: tip cells at the growing front and stalk cells in its EC receptor Frizzled4 (Fz4), coreceptor Lrp5, and receptor the vascular plexus behind the front. This division of endothelial chaperone Tspan12 activate canonical Wnt signaling in de- cell states is one of the central organizing principles of angiogen- veloping ECs (10). In humans and mice, defects in any of these esis. In the developing retina, Edn2 overexpression leads to components lead to retinal hypovascularization.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]